申请人:Luo Guanglin
公开号:US20130096130A1
公开(公告)日:2013-04-18
The disclosure generally relates to the novel compounds of formula I, including pharmaceutically acceptable salts, which are CGRP receptor antagonists. The disclosure also relates to pharmaceutical compositions and methods for using the compounds in the treatment of CGRP related disorders including migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases such as asthma, and chronic obstructive pulmonary disease (COPD).
本公开涉及一般与公式I有关的新化合物,包括药学上可以接受的盐,它们是CGRP受体拮抗剂。本公开还涉及药物组合物和使用这些化合物治疗CGRP相关疾病的方法,包括偏头痛和其他头痛、神经源性血管扩张、神经源性炎症、热损伤、循环休克、与绝经期相关的潮红、气道炎症性疾病如哮喘,以及慢性阻塞性肺病(COPD)。